中核鈦白(002145.SZ):擬以1億元將中合聚能33.6774%股權轉讓給常靈諮詢
格隆匯9月10日丨中核鈦白(002145.SZ)公佈,公司與肇慶市常靈信息諮詢中心(有限合夥)(以下簡稱“常靈諮詢”、“受讓方”)及相關方於2024年9月10日簽署《關於廣東中合聚能科技有限公司之股權轉讓協議》,公司將持有的廣東中合聚能科技有限公司(以下簡稱“中合聚能”、“標的公司”)33.6774%的股權(對應認繳註冊資本6,666.67萬元)以人民幣1億元的價格轉讓給常靈諮詢(以下簡稱“本次交易”)。本次交易完成後,公司持有中合聚能16.8387%的股權,中合聚能不再納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.